Molecular Tumor Board

One of Eleanor Scott Bell's earliest memories is of picking tobacco to supplement the family income. They were a family of nine with a large extended family — part of the Lumbee Tribe of NC, "People of the Dark Water."

The Duke Med Alumni News Fall '22 Issue's cover story is "Researchers at Duke are Creating More Precise Approaches to Stopping Tumors."

Learn how the Precision Cancer Medicine Initiative is advancing research, extending lives, and breaking down barriers to access.

Learn about new developments in next generation molecular sequencing tests at the DUHS Clinical Labs' Clinical Molecular Diagnostics Laboratory.

There's nothing like cancer, many survivors say, to remind you that nothing is guaranteed. Good or bad. Renee Garber got an unexpected "bonus year."

“I had always considered myself one of the healthiest people I knew ...”

Duke Cancer Institute has given stage 4 cancer survivor Milos Bogetic precious extra time with his wife and growing young son.

For some patients, targeted therapy is their best shot. The Molecular Tumor Board at DCI is matching more and more patients to approved therapies and clinical trials.

DCI was invited to join the elite international AACR Project GENIE consortium, whose registry contains clinical-grade cancer genomic sequencing data from nearly 71,000 patients & 80 major cancer types.